Second-line Maintenance Therapy in Ovarian Cancer: PARP Inhibitors

Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, discuss the importance of utilizing PARP inhibitors as second-line maintenance therapy in ovarian cancer and share valuable clinical insights.